Project Grant R43CA246853

The National Cancer Institute awarded Nuvox Pharma, L.L.C. $2,896,263 on September 22, 2025 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop blood-based biomarkers that distinguish pseudoprogression from true disease progression in glioblastoma patients treated with chemoradiation and dodecafluoropentane emulsion (DDFPE), an oxygen therapeutic. The work is performed in Tucson, Arizona with a completion date of August 31, 2027. The project tests two hypotheses:...

The National Cancer Institute awarded $400,000 to Zeest Bio Inc. on September 15, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a novel liver-specific positron emission tomography tracer for improved detection of metastatic tumors and assessment of liver function and biliary tract pathology. The recipient will complete preclinical testing and investigational new drug-enabling studies in preparation for first-in-human clinical trials. Current imaging...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $437,113 to Massachusetts Eye and Ear Infirmary on June 8, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop fluorescence lifetime imaging methods for quantifying in vivo PD-L1 target engagement in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitor monoclonal antibodies. The project addresses a...

The National Cancer Institute awarded Vesicle Therapeutics Inc. $400,000 on September 16, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a targeted antisense oligonucleotide therapy for head and neck squamous cell carcinoma. Vesicle Therapeutics is synthesizing and evaluating a thiomorpholino-based antisense oligonucleotide designed to selectively inhibit the oncogenic STAT3A isoform while preserving the tumor-suppressive STAT3B isoform. The Phase I project...

The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...

This Project Grant from the National Institutes of Health National Cancer Institute totaling $1,170,174 was awarded to Trevarx Biomedical, Inc. on April 1, 2021 with a completion date of March 31, 2022. The grant supports development of an optimized synthesis platform for the radiotracer [18F]FTT under the Cancer Treatment Research program (CFDA 93.395). Specifically, the funding will allow Trevarx Biomedical and the University of Pennsylvania to determine the best method for synthesizing...

The National Cancer Institute awarded Emory University $402,401 on May 6, 2026, for development of an F-18 imaging agent to measure glioma IDH1 mutant expression under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funded work develops a positron emission tomography tracer to non-invasively measure mutated cytosolic NADP+-dependent isocitrate dehydrogenase (IDH1) activity in low-grade glioma and secondary glioblastoma multiforme. IDH1 mutations occur in more than 70...

The National Cancer Institute awarded Virginia Commonwealth University $511,930 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify molecular determinants of response and resistance to TROP2-targeted antibody-drug conjugates and develop strategies to enhance therapeutic efficacy in triple-negative breast cancer and pancreatic adenocarcinoma. The project spans five years through July 31, 2031, with work performed in Richmond, Virginia. The research...

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...